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Abstract: A i m: The aim of our study was to report preliminary validation data on the EORTC trans-
lated, Polish version of the EORTC QLQ-ELD14 questionnaire to show that this tool is an acceptable 
and psychometrically robust measure to collect HRQoL data in Polish elderly patients with cancer.
M a t e r i a l s  a n d  M e t h o d s: Patients with histological confirmation of primary cancer were eligible 
for the study. All patients filled out the Polish version of the EORTC QLQ-ELD14 module in addition 
to EORTC QLQ-C30 and a demographic questionnaire. Standardized validity and reliability analyses 
were performed.
R e s u l t s: Sixty-five patients (41 females — 63.1%) were enrolled into the study, with a mean age of 
76.4 ± 5.7 years. Cronbach alpha coefficients, range 0.70–0.84, showed positive internal consistency. 
Satisfactory convergent and discriminant validity in multi-trait scaling analyses was seen. Strong cor-
relations were observed between the EORTC QLQ-ELD14 (especially mobility and burden of illness), 
and the EORTC QLQ-C30 (r = –0.30–(–0.83); p <0.001). 
C o n c l u s i o n s: Basing on the preliminary data from this study, the Polish version of the EORTC 
QLQ-ELD14 module is a reliable and valid tool for measuring HRQoL in elderly cancer patients. How-
ever further research is needed to establish the full psychometric properties of the described module, 
especially in regards to test-retest and responsiveness over time..
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INTRODUCTION
In recent years, in addition to the traditional cancer outcome measures such as over-
all survival, disease-free survival, and time to disease progression, also health-re-
lated quality-of-life (HRQoL) received recognition [1]. This signifies an important 
change in thinking, as in many cancer patients successful medical results often 
coexist with unsatisfactory outcomes from the patient’s own point of view [1, 2].
Over 50% of all new cancer diagnoses and over 60% of all cancer-related 
deaths occur in the elderly [3]. However, surprisingly despite the above men-
tioned fact, older people are still underrepresented in cancer clinical trials [4]. 
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The most probable reason that might explain this state is that the vast majority 
of elderly patients, even though they qualify for active treatment, will not finish 
their treatment plan due to high mortality [5]. Further issues that might restrict 
access of elderly people to the full panel of treatment options are comorbidities, 
low social support, and frailty [6, 7].
HRQoL in the elderly is a complex construct encompassing more than just 
mental and physical health and functioning [8]. What is more, HRQoL in old-
er patients is not linked to any specific medical condition [4]. A study by Wan 
et al. [9] has shown that it is cancer, and not age that impacts HRQoL in elder-
ly patients. What is interesting, elderly cancer patients can have better HRQoL 
when compared to cancer-free patients [8, 10].
Older people often have a different HRQoL profile, when compared with young-
er patients, due to their specific age-related needs [11]. Even though a broad 
spectrum of tools, able to measure both general (eg. SF-36) [12] and cancer-spe-
cific HRQoL (eg. European Organization for Research and Treatment of Cancer — 
EORTC QLQ-C30) [13] exists, up until recently the literature lacked question-
naires targeted to assess cancer-related HRQoL in the elderly. In 2013 Wheel-
wright et al. [14] published on behalf of the EORTC Quality-of-Life Group a man-
uscript describing the creation of the EORTC QLQ-ELD14 — a supplementary 
module to the EORTC QLQ-C30 that allows to assess the HRQoL of elderly pa-
tients with cancer. To date no tool for assessing HRQoL in elderly cancer patients 
is available in Polish.
The aim of our study was to report preliminary validation data on the EORTC 
translated, Polish version of the EORTC QLQ-ELD14 questionnaire to show that 
this tool is an acceptable and psychometrically robust measure to collect HRQoL 
data in Polish elderly patients with cancer. Our group has previous experience 
in performing this kind of validation studies [15, 16].
MATERIALS AND METHODS
PATIENTS
The patients were recruited prospectively between January 2014 and June 2014 
in one hospital and one private clinic in Krakow, Poland.
The research protocol was approved by the Jagiellonian University Ethics Com-
mittee (registry number KBET/187/B/2014). The study has been performed in 
accordance with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
Patients were eligible if they were above 70 years old and had histological 
confirmation of primary cancer. Exclusion criteria included lack of consent to 
participate in the study, inability to understand or complete the questionnaires, 
and a history of any other cancer than the primary. The patients included were 
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classified into groups based on their current Karnofsky Performance Status (KPS) 
(>80 or ≤80), having none or one or more Charlson comorbidity, and being on 
or off treatment [17].
InTERVIEW pROCEDuRE
The patients were approached during their visits at the outpatient clinics of the 
participating centers or during their stay at the clinic, and informed about the 
study. They were interviewed only after written informed consent was obtained. 
Each patient completed the Polish version of the EORTC QLQ-C30, the EORTC 
QLQ-ELD14 module and a questionnaire concerning demographic data together 
with the Charlson Comorbidity Index [18]. patients were provided the measures 
before undergoing planned treatment. The questionnaires were administered by 
a medical doctor.
QUESTIONNAIRES
The EORTC QLQ-C30 is a 30-item questionnaire comprised of a global health 
status, five multi-item functional scales, three multi-item symptom scales and six 
symptom single items. It is translated into over 85 languages [19], and is one of 
the most frequently used HRQoL measures in clinical trials [20].
The EORTC QLQ-ELD14 is a 14-item cancer-specific module composed of five 
multi-item scales that assess mobility (3 questions), worries about others (2 ques-
tions), future worries (3 questions), maintaining purpose (2 questions), and bur-
den of illness (2 questions). It also includes 2 single items regarding joint stiffness 
and family support. All questions of the EORTC QLQ-ELD14 have standardized 
scores ranging from 0 to 100, with higher scores indicating a greater degree of 
symptoms (worse HRQoL) (for questions number 31–34, 36–40, 43, 44), and 
a better HRQoL in case of questions number 35, 41, and 42 [14].
All of the EORTC QLQ-C30 and the EORTC QLQ-ELD14 multi-item scales 
and single items are scored on a 1- to 4-point Likert scale (‘not at all’, ‘a little’, 
‘quite a bit’, ‘very much’), apart from items 29 and 30 of the EORTC QLQ-C30, 
which are scored on a 1- to 7-point scale. Detailed information on how to score 
the EORTC questionnaires can be found in the EORTC QLQ-C30 scoring man-
ual and its addendum [21]. The questionnaire and the scoring manual were ob-
tained from the EORTC Quality of Life Department, upon request of the main 
author of the study.
STATISTICAL ANALYSIS
Several pre-planned standard psychometric tests were conducted, these approaches 
can be seen in the EORTC Module Development Guidelines [22, 23].
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Scoring of the two measures followed the standard EORTC scoring instruc-
tions. In short, scores for single items and multi-item functional and symptom 
scales were calculated by linear transformation of raw scores into a 0–100 score, 
with 100 representing best global health, functional status or worst symptoms 
— depending on the measuring property of each multi-item or single-item scale, 
as described by the EORTC Scoring Manual [21]. To analyze the data descriptive 
statistics (mean, standard deviation, percentage distribution) were used.
Convergent validity was assessed by correlating each item with its own scale. 
Discriminant validity was assessed by correlating each item with any other scale. 
Evidence of item convergent validity was defined as a correlation of 0.40 or great-
er between an item and its own scale (corrected for overlap). A scaling success 
for an item was seen when the correlation between an item and its own scale 
was significantly higher than its correlation with other scales [24]. Cronbach’s 
alpha coefficient was calculated to assess the internal consistency of the Polish 
version of the EORTC QLQ-ELD14. Internal consistency estimates of a magnitude 
of >0.70 were considered acceptable for group comparisons [24].
Clinical validity was assessed using the Wilcoxon rank sum nonparametric 
test. This assesses if the questionnaire was able to discriminate between sub-
groups of patients differing in clinical status. Known-groups used in this study 
were based on Karnofsky Performance Status (KPS), Charlson Comorbidity Index, 
and being on or off treatment. Differences between groups were tested with the 
Mann–Whitney test. Spearman correlation was used to assess the correlations 
between the EORTC QLQ-C30 and the EORTC QLQ-ELD14 scales.
The significance level was set at p <0.05. Statistical analysis was conducted 
using computer software Statistica 10.0 PL by StatSoft Poland (licensed to the 
Jagiellonian University Medical College).
The acceptability of the EORTC QLQ-ELD14 was assessed using the response 
rate, percentage of missing data, assistance and time needed to complete the 
questionnaire and details of items considered upsetting, confusing or difficult in 
the questionnaire.
RESULTS
PATIENT CHARACTERISTICS AND ACCEPTABILITY
During the 6-month recruitment period a total of 65 patients (41 females — 
63.1%) were enrolled into the study, with a mean age of 76.4 ± 5.7 years. pa-
tients’ clinical and demographic data are presented in Table 1.
No patients refused to participate in the study. All 65 patients answered both 
the EORTC QLQ-C30 and the EORTC QLQ-ELD14. Overall 6.1% of item respons-
es were missing.
In total 45 (69.2%) interviewees required assistance completing the question-
naires. The most commonly given justification were problems with eyesight and 
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T a b l e  1
patients’ clinical and demographic data.
Variable Overall n = 65
Age (mean±SD) 76.4 ± 5.7
Education (%)
Elementary 17 (26.2%)
High School 34 (52.3%)
University 14 (21.5%)
Current working status (%)
Employed (full-time)  2 (3.1%)
Employed (part-time) 11 (16.9%)
Retired/Pensioner 52 (80%)
Living (%)
Alone 21 (32.3%)
With partner or family 36 (55.4%)
With others (e.g. nursing home)  8 (12.3%)
Marital status (%)
Married 39 (60%)
Widowed 13 (20%)
Divorced  8 (12.3%)
Single  5 (7.7%)
primary tumour (%)
Breast 16 (24.6%)
Prostate 13 (20%)
Colorectal 12 (18.5%)
Head & Neck 12 (18.5%)
Lung  6 (9.2%)
Other  6 (9.2%)
Active treatment (%)
Yes 29 (44.6%)
No 36 (55.4%)
Karnofsky performance Status (%)
>80 43 (66.2%)
≤80 22 (33.8%)
Charlson Comorbidity Index (%)
No comorbidities 17 (26.2%)
One Charlson comorbidity 27 (41.5%)
More than one Charlson comorbidity 21 (32.3%)
SD — standard deviation.
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reading. The total time for completion of the questionnaires and interview was 
approximately 25 minutes without assistance and 34 minutes with assistance. 
Seven patients (10.8%) found questions 37–39 (relating to their and their family 
health in the future, and uncertainty of what the future might bring) upsetting. 
No patients reported the questions to be confusing or difficult.
RELIABILITY AND VALIDITY
Reliability, convergent and discriminant validity of EORTC QLQ-ELD14 multi-item 
scales and single items are presented in Table 2. Taking into account the EORTC 
QLQ-ELD14 its own-scale correlations were considered good. All item correlations 
within their own scales exceeded the 0.40 criterion, and were correlated higher 
with their own scale than with the other scales. All presented Cronbach alpha 
values exceeded the 0.7 criterion.
T a b l e  2 
Reliability, convergent and discriminant validity of QLQ-ELD14 multi-item scales and single items.
EORTC QLQ-ELD14 multi-item 
scale and single items*
Convergent 
validity1
Discriminant 
validity2
Cronbach's 
alpha
Mobility (3) 0.57–0.63 0.04–0.46 0.81
Joint stiffness (1) – 0.10–0.40 –
Family support (1) – 0.03–0.41 –
Worries about others (2) 0.51 0.06–0.37 0.70
Future worries (3) 0.70–0.79 0.04–0.55 0.84
Maintaining purpose (2) 0.59 0.09–0.28 0.71
Burden of illness (2) 0.62 0.04–0.52 0.83
SD — standard deviation; * — the number in brackets signify the number of questions in the scale/
signify a single item; 1 — Item-own scale correlation, Spearman correlation coefficient, corrected for 
overlap 2 — Item-other scale correlation, absolute values displayed, Spearman correlation coefficient.
Clinical validity assessment by known-group comparison is presented in Table 
3. There were significant differences between the groups in most of the EORTC 
QLQ-ELD14 scales and items.
Table 4 presents Spearman correlations values for correlations between the 
QLQ-C30 and the QLQ-ELD14 scales.
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T a b l e  3 
EORTC QLQ-ELD14 known group comparison.
EORTC QLQ-ELD14
On (n = 29)  
vs. Off Treatment  
(n = 36)
One (n = 27)  
vs. more than one  
(n = 21)  
Charlsoncomorbidity
KpS >80 (n = 43)  
vs. KPS ≤80  
(n = 22)
Mobility 42.7 vs. 29.0; 
p <0.0001
40.3 vs. 52.6; 
p <0.0001
16.6 vs. 51.3; 
p <0.0001
Joint stiffness 26.8 vs. 21.4; 
p <0.0001
37.1 vs. 45.4; 
p <0.0001
15.2 vs. 41.2; 
p <0.0001
Family support 79.3 vs. 70.9; 
p <0.0001
65.1 vs. 69.9; 
p<0.0001
68.4 vs. 82.0; 
p <0.0001
Worries about 
others
48.1 vs. 37.4; 
p <0.0001
37.7 vs. 37.0; 
p = 0.02
38.3 vs. 41.1; 
p <0.0001
Future worries 38.4 vs. 23.5; 
p <0.0001
29.5 vs. 37.2; 
p <0.0001
22.4 vs. 39.0; 
p <0.0001
Maintaining purpose 64.0 vs. 67.2; 
p <0.0001
68.6 vs. 61.4; 
p <0.0001
75.7 vs. 61.4; 
p <0.0001
Burden of illness 59.5 vs. 36.2; 
p <0.0001
36.5 vs. 50.1; 
p <0.0001
30.8 vs. 62.6; 
p <0.0001
Values presented as mean±SD; KpS — Karnofsky performance Status; SD — standard deviation
T a b l e  4 
Spearman correlations values for correlations between the QLQ-C30 and the QLQ-ELD14 scales.
Mobility
Joint  
stiffness
Family 
support
Worries 
about 
others
Future 
worries
Burden  
of illness
Maintaining 
purpose
Physical func-
tioning
–0.83* –0.50* 0.05 –0.12 –0.23 –0.45* 0.18
Social func-
tioning
–0.43* –0.29 0.11 –0.35 –0.40* –0.50* 0.24
Emotional 
functioning
–0.30 –0.23 0.17 –0.29 –0.51* –0.56* 0.31
Role  
functioning
–0.55* –0.31 0.06 –0.20 –0.33 –0.48* 0.15
Global health  
status/quality 
of life
–0.57* –0.39 0.19 –0.22 –0.43* –0.51* 0.29
* — r ≥0.4
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DISCUSSION
This study is a preliminary report aiming to establish the psychometric properties 
of the Polish version of the EORTC QLQ-ELD14 module in order to introduce it 
to clinical practice before the full validation data become available.
The EORTC QLQ-ELD14 module is different from other EORTC site-specific 
modules as it is applicable to patients with all kinds of malignancies, and has 
a stronger than normal focus on the psycho-social side of HRQoL problems [14].
As mentioned earlier, the elderly are still an underrepresented group in clin-
ical trials [4], especially those encompassing HRQoL as an outcome. This par-
tially stems from the fact, that in opposition to depression [25] or cognitive and 
physical disorders [26] instruments specifically tailored to assess HRQoL in the 
elderly have just recently been introduced [4, 14]. There is a need to complement 
classical oncologic outcomes with the use of measures of patients’ perception on 
disease impact and treatment consequences.
None of the 65 patients approached declined taking part in the study. This 
is an important information signifying both that the EORTC QLQ-ELD14 is an 
acceptable measure, and that elderly cancer patients are ready and open to dis-
cuss their HRQoL problems with healthcare professionals. The low percentage of 
missing responses further backs this theory, at the same time showing that there 
are only a few issues that a minority of older people might be reluctant to dis-
cuss. A significant portion of study participants required assistance when filling 
in the questionnaires. The most common reason given by the patients was that 
due to lack of proper reading glasses they were unable to read the questionnaires 
by themselves. In the future this might be solved by using computerized adap-
tive testing (CAT) [27] which, among other things, allows to enlarge the text font 
to the size readible by the patient. Even though the total number of questions 
was lower than in similar questionnaire administered to younger adults [12, 16, 
28], older patients required considerably more time to fill in the questionnaires. 
A minority of the participants found three questions of the EORTC QLQ-ELD14 
upsetting — from one side this can be a purely incidental finding. However, 
healthcare professionals would do wise to take this into account, and approach 
elderly cancer patients with appropriate patience and empathy — traits that can 
be easily lost in the busy modern medical environment [29, 30].
Similar to the original EORTC phase 4 study by Wheelwright et al. [14] the 
Polish version of the EORTC QLQ-ELD14 construct showed five multi-item scales 
and two single items characterized by appropriate reliability, convergent and dis-
criminant validity. The results of known-group comparison demonstrated that the 
EORTC QLQ-ELD14 module is able to successfully discriminate between patient 
subgroups differing in clinical status.
The correlations found between the EORTC QLQ-C30 and the EORTC QLQ-
ELD14 were not unexpected, and can be justified by the concept of the scales 
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themselves. These results point to the central role of mobility and burden of 
illness in the overall cancer-related HRQoL. The same was confirmed in the 
study by Wheelwright et al. [14]. What is interesting is the fact that psychomet-
ric analysis in the EORTC Phase 4 study [14] suggested to retain joint stiffness 
as a separate item from the mobility scale. This was further backed by qualita-
tive reports from patients in the EORTC Phase 1 study [4], showing that elderly 
people see joint stiffness as a separate entity, when contrasted with problems 
with mobility.
The main limitations of this study stem from the fact that this is a preliminary 
report aiming to rapidly introduce the Polish version of the EORTC QLQ-ELD14 
into clinical practice. The elements lacking in this manuscript i.e. responsiveness 
over time and test-retest will be assessed once the target sample size for the final 
analysis will be reached (n = 90–140; according to the proposal of Tabachnick 
and Fidell [31] stating that in order to obtain reliable estimates, the number of 
observations should be 5–10 times the number of questions in the questionnaire).
What appears to be the best application of the EORTC QLQ-ELD14 is to use 
it to supplement the EORTC QLQ-C30 (stacked together with an appropriate site- 
specific module) to fully evaluate generic issues affecting elderly people with can-
cer, that are not covered by the core module or its appropriate disease-specif-
ic add-on. Wheelwright et al. [14] suggest that the greatest use of the EORTC 
QLQ-ELD14 might be found when evaluating changes in cancer services across 
a range of tumor sites.
Clinicians should remember that even though new cancer treatment options 
arise almost every month, HRQoL should always accompany survival. Thus, the 
need for tools such as the one described in this study, which will hopefully help 
to include older Polish cancer patients in clinical trials having HRQoL as one of 
the endpoints.
Concluding, basing on the preliminary data from this study, the Polish ver-
sion of the EORTC QLQ-ELD14 module is a reliable and valid tool for measuring 
HRQoL in elderly cancer patients. However further research is needed to establish 
the full psychometric properties of the described module, especially in regards to 
test-retest and responsiveness over time.
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